Abstract: The present invention provides methods for purifying a polypeptide comprising a CH2/CH3 region, comprising binding the polypeptide to Protein A and eluting with a pH gradient starting at a low pH.

Abstract: Methods of treating patients having HER2-positive early breast cancer with the antibody-drug conjugate trastuzumab emtansine (T-DM1) are provided.

Abstract: The invention provides a compound represented by represented by the following structural formula: or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

Abstract: A method of reducing glycation of an amino acid in a protein produced by a host cell in cell culture medium is disclosed.

Abstract: The invention provides a compound represented by represented by the following structural formula: or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

Abstract: Various salt forms and free base of Compound (I) represented by the following formula are disclosed.

Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

Abstract: The invention provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

Abstract: Methods, systems, compositions, and computer program products are provided for accurately identifying candidate neoantigens that exhibit immunogenic properties. In some embodiments, a method provided herein includes receiving a set of candidate peptide sequences, each candidate peptide sequence in the set having a major histocompatibility complex (MHC) presentation score meeting a pre-set criterion. The method further includes identifying a corresponding MHC peptide sequence associated with each candidate peptide sequence in the set; generating immunogenicity input vectors from the set of candidate peptide sequences by processing a representation of each candidate peptide sequence in the set of candidate peptide sequences and a representation of the corresponding MHC peptide sequence for each candidate peptide sequence in the set.

Abstract: The invention provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

Abstract: The current invention reports a method for purifying an antibody by reducing the content of a host cell protein. The method employs a wash step with a low conductivity aqueous solution in an affinity chromatography.

Abstract: The present disclosure relates to compounds comprising a VHL ligand moiety and to methods of using such compounds as ligands of VHL. The present disclosure further relates to the use of the compounds described herein, or pharmaceutical compositions thereof, to prevent and/or treat a range of diseases, disorders, and conditions.

Abstract: The presently disclosed subject matter relates to “Randomized Configuration Targeted Integration” (also referred to herein as “Randomized Chain Targeted Integration”) (RCTI) strategies for the generation and identification of host cells capable of expressing recombinant proteins, e.g., monoclonal antibodies, as well as compositions derived from the same, e.g., bispecific antibodies, and other complex format proteins, e.g., membrane protein complexes and other difficult to express molecules.

Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidases SpsB and/or LepB, an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

Abstract: Embodiments disclosed herein generally relate to multi-arm machine learning models for lesion detection. Particularly, aspects of the present disclosure are directed to accessing a three-dimensional magnetic resonance imaging (MRI) images. Each of the three-dimensional MRI images depict a same volume of a brain of a subject. The volume of the brain includes at least part of one or more lesions. Each three-dimensional MRI image of the three-dimensional MRI images is processed using one or more corresponding encoder arms of a machine-learning model to generate an encoding of the three-dimensional MRI image. The encodings of the three-dimensional MRI images are concatenated to generate a concatenated representation. The concatenated representation is processed using a decoder arm of the machine-learning model to generate a prediction that identifies one or more portions of the volume of the brain predicted to depict at least part of a lesion.

Abstract: The present disclosure provides methods for treating lung cancer (such as small cell lung cancer, e.g., extensive stage small cell lung cancer) in an individual. The methods comprise administering to the individual a PD-1 axis binding antagonist (such as an anti-PD-L1 antibody, e.g., atezolizumab), a platinum agent (e.g., cisplatin or carboplatin), and a topoisomerase II inhibitor (e.g., etoposide).

Abstract: The present disclosure provides methods and kits for purifying an antigen binding protein comprising a VL domain using a Protein L chromatography material which includes kosmotrope salts in the buffer background.

Abstract: The present disclosure relates to techniques for privacy-preserving computing to protect a subject's privacy while using the subject's data for secondary purposes such as training and deploying artificial intelligence tools. Particularly, aspects are directed to receiving, at a local server, subject data regarding a first subject, performing, by the local server, a de-identifying operation, an anonymizing operation, or both on the subject data, sending the subject data to a remote server, receiving a production model from the remote server, the production model including parameters derived in part from the processed subject data, receiving, at the local server, subsequent data regarding a second subject, inputting, by the local server, the subsequent data into the production model to analyze the subsequent data and generate an inference or prediction from the analysis of the subsequent data; and sending, by the local server, the inference or the prediction to a computing device.

Abstract: Provided are CD8 binding agents comprising a VHH domain that specifically binds human CD8. Also provided are nucleic acids encoding such CD8 binding agents, vectors comprising such nucleic acids, host cells comprising same, and methods of making such CD8 binding agents. Also provided are CD8 binding agents having the VHH domain conjugated to a detectable label. Provided are methods of using such CD8 binding agents to detect CD8+ T cells, monitor disease progress, and monitor treatment progress in a subject having cancer, autoimmune disease or condition, transplant rejection or graft-versus-host disease.

Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof useful in the treatment of IRE1-related diseases and disorders described herein.